Q&A With Paul Hudson of AstraZeneca US: ADA Meeting Provides Unique Look at Diabetes Field

Video

With more than 10000 people in Boston for the American Diabetes Association's Scientific Sessions the event provides a chance for some of the top minds in the field to share information.

With more than 10000 people in Boston for the American Diabetes Association's Scientific Sessions the event provides a chance for some of the top minds in the field to share information.

Paul Hudson, President of AstraZeneca US discussed some of the areas of focus of the meeting which was held in Boston this year. Hudson said topics discussed include the latest technology and medicine as well as ways to control costs so patients can afford the treatment they need.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.